Immuneering Corp (IMRX)
1.64
+0.08
(+5.13%)
USD |
NASDAQ |
May 03, 16:00
1.64
0.00 (0.00%)
After-Hours: 20:00
Immuneering Net Income (Quarterly): -15.08M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -15.08M |
| September 30, 2023 | -12.60M |
| June 30, 2023 | -12.19M |
| March 31, 2023 | -13.60M |
| December 31, 2022 | -13.25M |
| September 30, 2022 | -12.84M |
| June 30, 2022 | -11.53M |
| March 31, 2022 | -12.90M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.78M |
| September 30, 2021 | -8.534M |
| June 30, 2021 | -7.988M |
| March 31, 2021 | -6.230M |
| December 31, 2020 | -5.836M |
| September 30, 2020 | -4.399M |
| June 30, 2020 | -3.604M |
| March 31, 2020 | -3.201M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-15.08M
Minimum
Dec 2023
-3.201M
Maximum
Mar 2020
-9.660M
Average
-11.16M
Median
Net Income (Quarterly) Benchmarks
| Geron Corp | -55.39M |
| SELLAS Life Sciences Group Inc | -8.136M |
| Elicio Therapeutics Inc | -8.949M |
| Vistagen Therapeutics Inc | -6.350M |
| ADMA Biologics Inc | -17.64M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 16.30M |
| EPS Diluted (Quarterly) | -0.52 |
| Enterprise Value | -37.03M |
| Earnings Yield | -115.2% |
| Normalized Earnings Yield | -117.07 |